(Circulation. 2002;105:360.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From the Cardiovascular Medicine and Gene Therapy Section, National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy (C.E., M.B.S., T.S., A.P., L.G., P.M.); Internal Medicine (P.M.) and Biomedical Sciences (G.P., L.G.), University of Sassari, Italy; Cardiovascular Research, St. Elizabeths Medical Center, Boston, Mass, USA (R.K., J.M.I.); Experimental and Clinical Medicine, University of Ferrara, Italy (D.R.); Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany (C.C., M.B.); and Biophysics, Universidade Federal de São Paulo, Brazil (J.B.P.).
Correspondence to Paolo Madeddu or Costanza Emanueli, Cardiovascular Medicine and Gene Therapy Section, INBB National Laboratory, viale SantAntonio, 07033 Osilo (Sassari), Italy. E-mail madeddu{at}yahoo.com or emanueli@yahoo.com
Background Kinins are modulators of cardiovascular function. After ischemic injury, enhanced kinin generation may contribute in processes responsible for tissue healing.
Methods and Results Using pharmacological and genetic approaches, we investigated the role of kinin B1 receptor in reparative angiogenesis in a murine model of limb ischemia. The effect of B1 pharmacological manipulation on human endothelial cell proliferation and apoptosis was also studied in vitro. Abrogation of B1 signaling dramatically inhibited the native angiogenic response to ischemia, severely compromising blood perfusion recovery. Outcome was especially impaired in B1 knockouts that showed a very high incidence of limb necrosis, eventually leading to spontaneous auto-amputation. Conversely, local delivery of a long-acting B1 receptor agonist enhanced collateral vascular growth in ischemic skeletal muscle, accelerated the rate of perfusion recovery, and improved limb salvage. In vitro, B1 activation stimulated endothelial cell proliferation and survival, whereas B1 antagonism induced apoptosis.
Conclusions Our results indicate that the B1 plays an essential role in the host defense response to ischemic injury. B1 signaling potentiation might be envisaged as a utilitarian target for the treatment of ischemic vascular disease.
Key Words: receptors, bradykinin angiogenesis ischemia muscle, skeletal endothelium
This article has been cited by other articles:
![]() |
D. Westermann, T. Walther, K. Savvatis, F. Escher, M. Sobirey, A. Riad, M. Bader, H.-P. Schultheiss, and C. Tschope Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy Diabetes, June 1, 2009; 58(6): 1373 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bader Kallikrein-Kinin System in Neovascularization Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 617 - 619. [Full Text] [PDF] |
||||
![]() |
O. A. Stone, C. Richer, C. Emanueli, V. van Weel, P. H.A. Quax, R. Katare, N. Kraenkel, P. Campagnolo, L. S. Barcelos, M. Siragusa, et al. Critical Role of Tissue Kallikrein in Vessel Formation and Maturation: Implications for Therapeutic Revascularization Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 657 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Bawolak, L. Gera, G. Morissette, J. Bouthillier, J. M. Stewart, L.-A. Gobeil, R. Lodge, A. Adam, and F. Marceau Fluorescent Ligands of the Bradykinin B1 Receptors: Pharmacologic Characterization and Application to the Study of Agonist-Induced Receptor Translocation and Cell Surface Receptor Expression J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 159 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Krankel, R. G. Katare, M. Siragusa, L. S. Barcelos, P. Campagnolo, G. Mangialardi, O. Fortunato, G. Spinetti, N. Tran, K. Zacharowski, et al. Role of Kinin B2 Receptor Signaling in the Recruitment of Circulating Progenitor Cells With Neovascularization Potential Circ. Res., November 21, 2008; 103(11): 1335 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, F. Tan, Y. Zhang, and R. A. Skidgel Carboxypeptidase M and Kinin B1 Receptors Interact to Facilitate Efficient B1 Signaling from B2 Agonists J. Biol. Chem., March 21, 2008; 283(12): 7994 - 8004. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Li, T. Kondo, Y. Numaguchi, K. Kobayashi, M. Aoki, N. Inoue, K. Okumura, and T. Murohara Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis Hypertension, February 1, 2008; 51(2): 252 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Isbell, S. Voros, Z. Yang, J. M. DiMaria, S. S. Berr, B. A. French, F. H. Epstein, S. P. Bishop, H. Wang, R. J. Roy, et al. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3372 - H3378. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gera, J.-P. Fortin, A. Adam, J. M. Stewart, and F. Marceau Discovery of a Dual-Function Peptide That Combines Aminopeptidase N Inhibition and Kinin B1 Receptor Antagonism J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 300 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Fortin, L. Gera, J. Bouthillier, J. M. Stewart, A. Adam, and F. Marceau Endogenous Aminopeptidase N Decreases the Potency of Peptide Agonists and Antagonists of the Kinin B1 Receptors in the Rabbit Aorta J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1169 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kintsurashvili, A. Duka, I. Ignjacev, G. Pattakos, I. Gavras, and H. Gavras Age-related changes of bradykinin B1 and B2 receptors in rat heart Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H202 - H205. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Pelorosso, P. T. Brodsky, C. L. Zold, and R. P. Rothlin Potentiation of des-Arg9-Kallidin-Induced Vasoconstrictor Responses by Metallopeptidase Inhibition in Isolated Human Umbilical Artery J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1355 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Liesmaa, A. Kuoppala, N. Shiota, J. O. Kokkonen, K. Kostner, M. Mayranpaa, P. T. Kovanen, and K. A. Lindstedt Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2317 - H2322. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Madeddu Therapeutic angiogenesis and vasculogenesis for tissue regeneration Exp Physiol, May 1, 2005; 90(3): 315 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L.M. Cruden, G. H. Tse, K. A.A. Fox, C. A. Ludlam, I. Megson, and D. E. Newby B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 772 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Song, I. M. Sainz, S. C. Cosenza, I. Isordia-Salas, A. Bior, H. N. Bradford, Y.-L. Guo, R. A. Pixley, E. P. Reddy, and R. W. Colman Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen Blood, October 1, 2004; 104(7): 2065 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Levy Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System Circulation, January 6, 2004; 109(1): 8 - 13. [Full Text] [PDF] |
||||
![]() |
A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Q. Miao, V. Chen, L. Chao, and J. Chao Structural elements of kallistatin required for inhibition of angiogenesis Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1604 - C1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimizu, H. Okamoto, S. Chiba, Y. Matsui, T. Sugawara, M. Akino, J. Nan, H. Kumamoto, H. Onozuka, T. Mikami, et al. VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts Cardiovasc Res, April 1, 2003; 58(1): 203 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Q. Miao, J. Agata, L. Chao, and J. Chao Kallistatin is a new inhibitor of angiogenesis and tumor growth Blood, October 16, 2002; 100(9): 3245 - 3252. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Milia, M. B. Salis, T. Stacca, A. Pinna, P. Madeddu, M. Trevisani, P. Geppetti, and C. Emanueli Protease-Activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia Circ. Res., August 23, 2002; 91(4): 346 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Emanueli, M. B. Salis, A. Pinna, T. Stacca, A. F. Milia, A. Spano, J. Chao, L. Chao, L. Sciola, and P. Madeddu Prevention of Diabetes-Induced Microangiopathy by Human Tissue Kallikrein Gene Transfer Circulation, August 20, 2002; 106(8): 993 - 999. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |